Research on drug-induced liver injury in association with co-infections and anti-tuberculosis drugs
by Li-Ya Wu; Sung-Shun Weng; Wing-Wai Wong
International Journal of Business and Systems Research (IJBSR), Vol. 14, No. 2, 2020

Abstract: This study uses data mining techniques to find out the risk factors for the tuberculosis (TB) patients with drug-induced liver injury (DILI). The Taiwan National Health Insurance Database is used for collection of domestic TB cases during 2004-2011 to study these TB patients and their drug prescribing patterns in order to build a model to predict the risk of drug-drug interaction between hepatitis B and C, acquired immune deficiency syndrome (AIDS) and TB. The results out of the total 188,032 TB patients have shown that 77,574 have taken anti-TB drugs. Afterwards, DILI occurred in 0.7% of the cases. Besides, for those DILI patients associated with TB and hepatitis B or C, this study reveals that DILI is associated with the use of ethambutol and rifampin. It is suggested that TB patients associated with hepatitis C should pay attention to their uses of rifampicin, and TB patients (especially males) associated with hepatitis B should pay attention to the ethambutol's impact on DILI. Moreover, our results also showed that having both AIDS and TB shows no significant effect on DILI.

Online publication date: Thu, 02-Apr-2020

The full text of this article is only available to individual subscribers or to users at subscribing institutions.

 
Existing subscribers:
Go to Inderscience Online Journals to access the Full Text of this article.

Pay per view:
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.

Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Business and Systems Research (IJBSR):
Login with your Inderscience username and password:

Username:        Password:          Forgotten your password?

Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.

If you still need assistance, please email subs@inderscience.com